JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

Search

CRISPR Therapeutics AG

Închisă

SectorSănătate

45.87 -8.55

Rezumat

Modificarea prețului

24h

Curent

Minim

45.52

Maxim

50.17

Indicatori cheie

By Trading Economics

Venit

102M

-106M

Vânzări

-3K

889K

Marjă de profit

-11,973.116

Angajați

393

EBITDA

101M

-101M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+33.9% upside

Dividende

By Dow Jones

Următoarele câștiguri

9 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-746M

4.9B

Deschiderea anterioară

54.42

Închiderea anterioară

45.87

Sentimentul știrilor

By Acuity

10%

90%

5 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

CRISPR Therapeutics AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 feb. 2026, 00:00 UTC

Acțiuni populare

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4 feb. 2026, 22:55 UTC

Câștiguri

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4 feb. 2026, 21:44 UTC

Câștiguri

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4 feb. 2026, 21:39 UTC

Câștiguri

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5 feb. 2026, 00:00 UTC

Câștiguri

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5 feb. 2026, 00:00 UTC

Câștiguri

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4 feb. 2026, 23:46 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4 feb. 2026, 23:45 UTC

Câștiguri

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4 feb. 2026, 23:32 UTC

Market Talk

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4 feb. 2026, 22:59 UTC

Achiziții, Fuziuni, Preluări

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4 feb. 2026, 22:30 UTC

Câștiguri

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4 feb. 2026, 22:30 UTC

Câștiguri

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4 feb. 2026, 22:21 UTC

Câștiguri

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 feb. 2026, 22:17 UTC

Market Talk

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4 feb. 2026, 22:15 UTC

Market Talk

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4 feb. 2026, 22:00 UTC

Market Talk

ESG Roundup: Market Talk

4 feb. 2026, 21:53 UTC

Câștiguri

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4 feb. 2026, 21:51 UTC

Câștiguri

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 feb. 2026, 21:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

4 feb. 2026, 21:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

4 feb. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 feb. 2026, 21:45 UTC

Câștiguri

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4 feb. 2026, 21:44 UTC

Câștiguri

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4 feb. 2026, 21:43 UTC

Câștiguri

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4 feb. 2026, 21:41 UTC

Câștiguri

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb. 2026, 21:36 UTC

Market Talk

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4 feb. 2026, 21:30 UTC

Câștiguri

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 feb. 2026, 21:30 UTC

Câștiguri

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 feb. 2026, 21:30 UTC

Câștiguri

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Comparație

Modificare preț

CRISPR Therapeutics AG Așteptări

Obiectiv de preț

By TipRanks

33.9% sus

Prognoză pe 12 luni

Medie 69.63 USD  33.9%

Maxim 105 USD

Minim 40 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCRISPR Therapeutics AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

11

Cumpărare

7

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

33.5 / 38.27Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

5 / 352 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat